#Aramchol #Galmed #Tissue Dynamics

Unveiling a Revolutionary Approach to Cardiac Fibrosis

In a groundbreaking study, Tissue Dynamics Ltd. and Galmed Pharmaceuticals Ltd. have unveiled a previously unknown metabolic pathway associated with cardiac fibrosis and heart failure. Utilizing advanced human cardiac organoid models, this initiative sets a new precedent for research in the field, overcoming the limitations posed by traditional animal studies.

This collaborative research aims to address a significant gap in the treatment of cardiac conditions, particularly cardiac fibrosis, a condition that occurs when the heart muscle becomes thickened and scarred, ultimately hindering its ability to function properly. It has long been recognized as a major contributor to heart failure, yet therapeutic options to reverse its progression remain scarce.

Insights from Human Cardiac Organoids

The research project successfully identified a metabolic mechanism specifically active in humans, marking a critical milestone in understanding cardiac disease biology. Through the use of Tissue Dynamics' advanced robotic DynamiX® platform in conjunction with the organoid models, researchers were able to achieve results that animal models could not provide.

The study's findings demonstrated that the combination of Aramchol Meglumine, an SCD1 inhibitor, and a selective PPARα agonist significantly reduced or